Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Surgical Oncology

The Decision: Surgery and Your "New Normal"

At a Glance

A prophylactic total gastrectomy (PTG) is the only definitive way to prevent stomach cancer in individuals with CDH1 or CTNNA1 mutations. Patients must weigh the permanent physical adjustments of living without a stomach against the emotional toll and inherent risks of intensive surveillance.

Deciding whether to have your stomach removed is a monumental, life-altering choice. For many with a CDH1 or CTNNA1 mutation, it is a choice between two difficult paths: the physical cost of surgery or the emotional weight of uncertainty [1][2].

The Standard of Care: Prophylactic Total Gastrectomy (PTG)

A prophylactic total gastrectomy (PTG) is a surgery to remove the entire stomach before cancer is found. It is the only way to definitively eliminate the risk of developing invasive diffuse gastric cancer [3][4].

  • Why it’s recommended: Because this cancer often grows invisibly beneath the surface, surveillance can miss early signs. Removing the stomach is the “gold standard” for prevention [5][6].
  • The Surgery: Surgeons perform a procedure often called a Roux-en-Y esophagojejunostomy, which means they reconnect the esophagus (your food pipe) directly to the small intestine. Over time, the small intestine adapts to hold and process food [7].
  • The Timeline: You can typically expect a hospital stay of 5 to 10 days, and a full initial recovery period of several weeks before returning to normal activities.
  • The Age Window: 2020 guidelines generally recommend this surgery between the ages of 18 and 40. However, the decision should be individualized based on your family history—often starting 5 to 10 years before the age of the youngest cancer diagnosis in your family [5][8].

The Trade-Off: Surgery vs. Surveillance

There is no “perfect” choice, only the choice that is right for your life and your risk tolerance.

Prophylactic Surgery (PTG) Intensive Surveillance
The Benefit Peace of Mind: Eliminates the risk of stomach cancer [5]. Physical Preservation: Keeps your stomach and natural digestive process intact [8].
The Cost Physical Toll: Significant weight loss, nutritional changes, and lifelong vitamin shots (like B12) [9][10]. Psychological Toll: “Scanxiety” and the risk that cancer could be missed despite best efforts [1][6].
Follow-up Lifetime monitoring with a dietitian and surgeon [9]. Annual, intensive endoscopies (Cambridge Protocol) [5].

The “Incidental” Discovery & CTNNA1

If your mutation was found “incidentally” (meaning you have no family history of stomach cancer) or if you have a CTNNA1 mutation, the decision may be even more complex.

  • Lower Penetrance: CTNNA1 is often considered a “moderate” risk gene compared to the “high” risk CDH1. The timing for surgery in these cases is not as strictly defined and depends heavily on your personal and family history [11][12].
  • Expert Consensus: In these situations, your team may lean more toward intensive surveillance in an expert center while you weigh your options [8][13].

Making the Decision

This is a multidisciplinary decision. You should not make it alone. Your team should include:

  1. A Surgical Oncologist: Who performs high volumes of these specific surgeries [14].
  2. A Genetic Counselor: To help you understand the risks specific to your mutation [15].
  3. A Specialized Dietitian: To walk you through what your diet will look like post-surgery [9].
  4. A Mental Health Professional: To help you process the significant emotional impact of this choice [16].

Remember: Choosing to wait is a choice, and choosing to have surgery is a choice. Both are valid ways to manage your health [8][1].

Next Steps: Learn how life changes post-surgery in Life Without a Stomach: Nutrition and Survivorship.
Back to the start: Home Page

Common questions in this guide

What is a prophylactic total gastrectomy (PTG)?
A prophylactic total gastrectomy is a preventative surgery to remove the entire stomach before cancer develops. It is considered the gold standard for preventing diffuse gastric cancer in high-risk individuals.
At what age should I get my stomach removed for a CDH1 mutation?
Current guidelines generally recommend preventative stomach removal between ages 18 and 40 for CDH1 mutation carriers. However, the exact timing should be individualized, often starting 5 to 10 years before the youngest stomach cancer diagnosis in your family.
Can I keep my stomach and just do cancer screenings instead?
Yes, intensive surveillance through specialized endoscopies is an alternative for those who wish to delay or avoid surgery. However, this approach carries the risk that cancer could be missed, as diffuse gastric cancer often grows invisibly beneath the stomach lining.
How will I digest food if my stomach is removed?
During surgery, doctors connect your esophagus directly to your small intestine in a procedure called Roux-en-Y esophagojejunostomy. Over time, your small intestine adapts to hold and process food, though you will need to adjust your diet and receive lifelong vitamin injections.
Do I need my stomach removed immediately if I have a CTNNA1 mutation?
Not necessarily. Because CTNNA1 is considered a moderate-risk gene compared to CDH1, the timeline for surgery is less strictly defined. Experts often lean toward intensive surveillance in a specialized center while you weigh your options based on your personal and family history.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many prophylactic total gastrectomies do you perform each year for patients with CDH1 or CTNNA1 mutations?
  2. 2.Given my specific family history, what is your recommended 'window' of age for me to have this surgery?
  3. 3.Can you connect me with a specialized dietitian who has experience managing patients without a stomach?
  4. 4.If I choose surveillance for now, what is the 'trigger' or finding that would make you recommend immediate surgery?
  5. 5.What is your hospital's protocol for post-operative recovery and long-term vitamin/nutritional monitoring?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Psychosocial Impacts of Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer: A Narrative Review.

    Kearns O, Snyder D, Davis J, et al.

    Psycho-oncology 2025; (34(10)):e70304 doi:10.1002/pon.70304.

    PMID: 41130910
  2. 2

    Unique challenges of risk-reducing surgery for hereditary diffuse gastric cancer syndrome: a narrative review.

    Gallanis AF, Davis JL

    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2023; (32(4)):391-395 doi:10.1097/CEJ.0000000000000798.

    PMID: 36977191
  3. 3

    Outcomes after prophylactic gastrectomy for hereditary diffuse gastric cancer.

    van der Kaaij RT, van Kessel JP, van Dieren JM, et al.

    The British journal of surgery 2018; (105(2)):e176-e182 doi:10.1002/bjs.10754.

    PMID: 29341148
  4. 4

    Pioneering use of genetic analysis for CDH1 to identify candidates for prophylactic total gastrectomy to prevent hereditary diffuse gastric cancer.

    Mokhtari-Esbuie F, Szeglin B, Ravari MR, et al.

    eGastroenterology 2023; (1(2)) doi:10.1136/egastro-2023-100017.

    PMID: 38188186
  5. 5

    Endoscopic Ultrasound Has Limited Utility in Diagnosis of Gastric Cancer in Carriers of CDH1 Mutations.

    Kumar S, Katona BW, Long JM, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2020; (18(2)):505-508.e1 doi:10.1016/j.cgh.2019.04.064.

    PMID: 31077828
  6. 6

    Random biopsies in patients harboring a CDH1 mutation: time to change the approach?

    Castro R, Lobo J, Pita I, et al.

    Revista espanola de enfermedades digestivas 2020; (112(5)):367-372 doi:10.17235/reed.2020.6720/2019.

    PMID: 32338015
  7. 7

    Conditional Relative Survival Among Patients With Gastric Cancer Undergoing Surgery: A Hospital-Based Cohort Study.

    Park H, Cho YS, Park DJ, et al.

    Journal of gastric cancer 2025; (25(4)):581-592 doi:10.5230/jgc.2025.25.e45.

    PMID: 41093777
  8. 8

    Hereditary diffuse gastric cancer: updated clinical practice guidelines.

    Blair VR, McLeod M, Carneiro F, et al.

    The Lancet. Oncology 2020; (21(8)):e386-e397 doi:10.1016/S1470-2045(20)30219-9.

    PMID: 32758476
  9. 9

    International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study.

    Roberts G, Benusiglio PR, Bisseling T, et al.

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2022; (25(6)):1094-1104 doi:10.1007/s10120-022-01318-5.

    PMID: 35831514
  10. 10

    Pregnancy, delivery, and breastfeeding after total gastrectomy for gastric cancer: a case report.

    Higashizono K, Nomura S, Yagi K, et al.

    World journal of surgical oncology 2018; (16(1)):229 doi:10.1186/s12957-018-1531-2.

    PMID: 30497494
  11. 11

    Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls.

    Lobo S, Dias A, Pedro AM, et al.

    Gut 2026; (75(5)):872-885 doi:10.1136/gutjnl-2024-334601.

    PMID: 40998418
  12. 12

    Cancer predisposition and germline CTNNA1 variants.

    Lobo S, Benusiglio PR, Coulet F, et al.

    European journal of medical genetics 2021; (64(10)):104316 doi:10.1016/j.ejmg.2021.104316.

    PMID: 34425242
  13. 13

    A Systematic Review of Surgical and Pathological Outcomes in Patients With a CDH1 Mutation Undergoing Total Gastrectomy.

    Khiabany A, Dermanis AA, Liew MS, et al.

    Journal of surgical oncology 2024; (130(8)):1539-1550 doi:10.1002/jso.27855.

    PMID: 39257226
  14. 14

    Emerging Adults Carrying a CDH1 Pathogenic or Likely Pathogenic Variant Face Diet and Lifestyle Challenges after Total Gastrectomy.

    Liu Y, Lopez R

    Journal of the Academy of Nutrition and Dietetics 2022; (122(5)):913-917 doi:10.1016/j.jand.2021.12.012.

    PMID: 34968751
  15. 15

    CDH1 variants leading to gastric cancer risk management decision-making experiences in emerging adults: 'I am not ready yet'.

    Liu Y, Calzone K, Fasaye GA, Quillin J

    Journal of genetic counseling 2021; (30(4)):1091-1104 doi:10.1002/jgc4.1393.

    PMID: 33655597
  16. 16

    Becoming and being a parent with an inherited predisposition to diffuse gastric cancer: A qualitative study of young adults with a CDH1 pathogenic variant.

    Tutty E, Forbes Shepherd R, Hoskins C, et al.

    Journal of psychosocial oncology 2023; (41(3)):286-302 doi:10.1080/07347332.2022.2104676.

    PMID: 35959852

This page discusses preventative surgical and surveillance options for hereditary diffuse gastric cancer for educational purposes only. Always consult your surgical oncologist and genetic counselor to make the best medical decisions for your specific mutation and lifestyle.

Get notified when new evidence is published on Hereditary diffuse gastric cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.